A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation
Open Access
- 15 December 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (2), 234-242
- https://doi.org/10.1016/j.jcf.2020.11.003
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Cystic fibrosisThe Lancet, 2016
- Progress in therapies for cystic fibrosisThe Lancet Respiratory Medicine, 2016
- Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutationJournal of Cystic Fibrosis, 2014
- A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defectThe Lancet Respiratory Medicine, 2013
- Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and FunctionCell, 2012
- Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved SequencesCell, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences of the United States of America, 2011
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences of the United States of America, 2009
- Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutationNature, 1991